Intensive Care Unit, Medizinische Klinik Innenstadt (Ludwig-Maximilians-Universität), Munich, Germany.
Resuscitation. 2013 Oct;84(10):1382-6. doi: 10.1016/j.resuscitation.2013.03.021. Epub 2013 Mar 22.
Prognostication of cardiac arrest survivors is challenging since therapeutic hypothermia (TH) has been introduced. We evaluated serum biomarkers and motor response.
This was a retrospective data analysis including patients in the years 2007-2012. Blood was drawn and a neurological examination was performed on admission and every morning. Outcomes were evaluated 6 months after discharge and dichotomized into good (cerebral performance category (CPC)=1 or 2) and poor (CPC=3, 4 or 5).
123 patients (79.7% male, 63±14 years) received TH; 50% had a good outcome. On admission, S-100B (P=0.004) was significantly associated with the outcome, as well as neuron-specific enolase (NSE; P=0.020) and S-100B (P=0.004) on day 1 after admission. NSE on day 2, NSE progression from day 1 to 2 and motor response on day 3 also predicted the outcome (all P<0.001). NSE>33μgl(-1) only predicted a poor outcome with a specificity of 76%. An absent motor response on day 3 was the most sensitive marker (94%). NSE>41.1μgl(-1) combined with S-100B>0.461μgl(-1) on day 1 was the most specific marker (96%).
Although NSE and S-100B levels are associated with the outcome, the use of previously described cut-off values was insufficiently predictive of neurologic outcome. Caution should be exercised in the use of these tests to provide neuroprognostication.
自治疗性低温(TH)引入以来,对心脏骤停幸存者的预后预测具有挑战性。我们评估了血清生物标志物和运动反应。
这是一项回顾性数据分析,包括 2007 年至 2012 年期间的患者。入院时和每天早上抽取血液并进行神经检查。出院后 6 个月评估结局,并分为良好(脑功能分类(CPC)=1 或 2)和不良(CPC=3、4 或 5)。
123 例患者(79.7%为男性,63±14 岁)接受了 TH;50%的患者结局良好。入院时,S-100B(P=0.004)与结局显著相关,入院后第 1 天神经元特异性烯醇化酶(NSE;P=0.020)和 S-100B(P=0.004)也与结局相关。第 2 天的 NSE、第 1 天至第 2 天的 NSE 进展以及第 3 天的运动反应也预测了结局(均 P<0.001)。NSE>33μg/l(仅)预测不良结局,特异性为 76%。第 3 天无运动反应是最敏感的标志物(94%)。第 1 天 NSE>41.1μg/l(联合 S-100B>0.461μg/l)是最特异的标志物(96%)。
尽管 NSE 和 S-100B 水平与结局相关,但使用先前描述的临界值预测神经结局的效果不足。在使用这些检测进行神经预后评估时应谨慎。